CA
NZ
UK
AU
IND
US
Eos Energy Enterprises, Inc. (NASDAQ: EOSE) has achieved revenue of $68 million, driven by increased demand for its long-duration energy storage solutions. This significant revenue growth is a testament to the company's expanding manufacturing capacity. As a result, investors can expect a substantial boost …
The surge sent ripples through global energy markets, lifting shares of refiners, drillers, and integrated oil majors while stoking concerns over inflationary pressures. Analysts noted that even limited disruptions could tighten crude supplies, particularly if Iran retaliates by targeting oil infrastructure or choking off …
With these additions, Phio's total issued patent portfolio now stands at 54 patents, a substantial intellectual property estate for a clinical-stage biotech company of Phio's size. Building a robust patent portfolio is a critical strategic priority for companies developing novel therapeutic platforms, as it …
This policy expansion serves as an important validation of the clinical utility of Quanterix's blood-based Alzheimer's diagnostic platform. Major insurers like Anthem typically conduct extensive clinical evidence review before extending coverage to a novel diagnostic test, meaning this coverage decision reflects a degree of …
VDPHL01 is a specialized gel-matrix oral minoxidil engineered for extended release, designed to sustain therapeutic growth-promoting levels of the drug while mitigating cardiovascular risks that have historically been linked to traditional immediate-release oral minoxidil formulations. This extended-release engineering approach represents an important potential advancement, …
The financing structure includes 6,027,399 shares priced at $18.25 per share, alongside 4,931,506 pre-funded warrants priced at $18.2499 each, issued to institutional investors with a nominal $0.0001 exercise price. Pre-funded warrants are a financing structure commonly used when certain institutional investors prefer to avoid …
A particularly notable aspect of this disclosure is that the data represents independent verification of ERNA-101's anti-tumor activity, rather than solely internally generated results. Independent confirmation of preclinical findings adds meaningful credibility to a drug candidate's underlying scientific rationale, as it reduces the risk …
IND clearance represents a foundational regulatory milestone for any clinical-stage biotech company, as it grants formal FDA authorization to begin testing an investigational therapy in human subjects. For Atrium, this clearance marks the transition of ATR 1072 from preclinical development into the clinical testing …
Under the terms of the transaction, Lōkahi securityholders received a combination of common and convertible preferred stock, an arrangement expected to yield approximately 90% fully diluted ownership of the combined company once the preferred shares convert. This ownership structure makes clear that Lōkahi is …
The revised guidance range accompanies preliminary first-half 2026 results that already showed clear signs of deteriorating performance, with first-half revenue of €300.1 million and an adjusted EBITDA loss of €42.7 million for the six-month period. Extrapolating the revised full-year range implies continued challenging conditions …
Please wait processing your request...